Clarient (Aliso Viejo, California) has regained Nasdaq compliance because the closing bid price of its common stock has been at $1 per share or more for at least 10 consecutive business days. The company received notice from Nasdaq in July that its common stock was subject to delisting as a result of failure to maintain the minimum bid price of $1 over the previous 30 consecutive business days.
Clarient is a technology and services resource for pathologists, oncologists and the pharmaceutical industry.
Apogee out of compliance with AMEX
Apogee Technology (Norwood, Massachusetts) was notified Nov. 1 that it does not meet certain continued listing standards, as set forth in the AMEX company guide and has therefore become subject to the procedures and requirements of Section 1009 of the company guide.
Apogee’s shareholders’ equity was about $3.97 million as of June 30 — less than the required $4 million — and losses from continuing operations and/or net losses in three out of its four most recent fiscal years. The company is also not in compliance with another section of the company guide as it has shareholders’ equity of less than $6 million and losses from continuing operations in its five most recent fiscal years.
Apogee must submit a plan by Dec. 1 advising of actions to bring the company into compliance within a maximum of 12 months. If the plan is accepted, Apogee will be permitted to continue its listing during the plan period, but such continued listing will be subject to periodic review. The company said it intends to issue a formal plan to AMEX before Dec. 1.
Apogee develops device and sensor products using its microsystems and nanotechnology for the medical, automotive, industrial and consumer markets.
Custom-Grown Bladders makes ‘Best’ list
Custom-grown bladders have made Popular Science (New York) magazine’s list of 100 breakthroughs that merit the magazine’s “Best of What’s New” award. Appearing in the December issue of Popular Science — the most widely read issue of the year, according to the magazine — “Best of What’s New” celebrates the 100 most impressive advancements in 10 categories, including Health.
This year, the magazine’s editors have recognized custom-grown bladders as the first complex organ that’s been successfully grown and transplanted. Tissue engineer Anthony Atala of Wake Forest University (Winston-Salem, North Carolina) and his colleagues grew the custom-made bladders from patients’ own cells which have been transplanted successfully, according to Popular Magazine.
This year, Atala reported that none of the seven patients who received the organs four years ago suffered the rejection problems that commonly plague transplant patients, the magazine notes.